Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility

被引:20
作者
Guis, S
Bendahan, D
Kozak-Ribbens, G
Figarella-Branger, D
Mattei, JP
Pellissier, JF
Treffouret, S
Bernard, V
Lando, A
Cozzone, PJ
机构
[1] Fac Med Marseille, UMR CNRS 6612, Ctr Resonance Magnet Biol & Med, F-13005 Marseille, France
[2] Hop Enfants La Timone, Marseille, France
[3] Hop Nord Marseille, Marseille, France
来源
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH | 2003年 / 49卷 / 02期
关键词
D O I
10.1002/art.11013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:237 / 238
页数:2
相关论文
共 13 条
[1]   A noninvasive investigation of muscle energetics supports similarities between exertional heat stroke and malignant hyperthermia [J].
Bendahan, D ;
Kozak-Ribbens, G ;
Confort-Gouny, S ;
Ghattas, B ;
Figarella-Branger, D ;
Aubert, M ;
Cozzone, PJ .
ANESTHESIA AND ANALGESIA, 2001, 93 (03) :683-689
[2]  
ELLIS FR, 1984, BRIT J ANAESTH, V56, P1267
[3]   Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro [J].
Flint, OP ;
Masters, BA ;
Gregg, RE ;
Durham, SK .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 145 (01) :91-98
[4]   Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia [J].
Gholami, K ;
Tavakoli, N ;
Maleki, M ;
Shafiee, A .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1998, 23 (03) :213-221
[5]  
Guis S, 2001, J RHEUMATOL, V28, P1405
[6]   EFFECTS OF COMBINED BEZAFIBRATE-SIMVASTATIN APPRAISED IN HEALTHY-SUBJECTS [J].
HORSMANS, Y ;
DESAGER, JP ;
HARVENGT, C .
JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 32 (05) :422-426
[7]   Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia [J].
Iliadis, EA ;
Rosenson, RS .
CLINICAL CARDIOLOGY, 1999, 22 (01) :25-28
[8]   Rhabdomyolysis following severe physical exercise in a patient with predisposition to malignant hyperthermia [J].
Kochling, A ;
Wappler, F ;
Winkler, G ;
Esch, JSA .
ANAESTHESIA AND INTENSIVE CARE, 1998, 26 (03) :315-318
[9]  
Leeb T, 1998, INT J MOL MED, V2, P293
[10]  
MARNINI P, 1992, INT J CLIN PHARM RES, V12, P65